David Larwood Email and Phone Number

Innovative drug development of a rare disease therapeutic. advancing growth through meticulous planning and execution. • Persistent strategic vision: Leading development of a life-altering superior antifungal therapeutic, coordinating product manufacturing operations and business development strategies, from initial research to clinical trials, driving growth and advancement. ✓ Strategized development of drug manufacture through commercial introduction of a superior therapeutic that eliminated disease in accepted animal models, safe in humans.✓ Executed a comprehensive long-term roadmap for product development of Nikkomycin-Z to Phase 2-ready, planning into future commercialization presented at more than 10 investor pitches. • Led and managed approximately $8M in NIH-supported development projects, spending extensive time in the lab and contributing to manufacturing process improvements critical for GMP product development at multi-kg scale. ✓ Collaborated with manufacturing partners to define, test, and optimize large-scale manufacturing✓ Organized and managed development and pilot scale manufacturing of API, including a $3M stimulus grant (RC3, 2009-2013) and a $2.2M grant to advance a Phase 2a trial (2014-2019). ✓ Directed development of novel therapeutic, improving historical cGMP process and preparing for FDA CMC filing, and planning Phase 2 clinical trial protocols and operations • Spearheaded public engagement, offering pioneering clinical trial strategies and impactful management insights. ✓ Decades of immersion at the annual Coccidioidomycosis Study Group, presented three talks, five abstracts, and a poster✓ Repeat presenter at investor meetings, typically 15 minutes, at JPM Biotech Showcase (9 times), BioFutures, BioInvestors, BIO.✓ Invited Speaker at Arena International Events Clinical Trials Outsourcing, Clinical Trial Supplies, and other annual conferences presenting >15 25-minute talks, moderating panels, and chairing ten 2-day meetings.

• Led development and scientific rationale for new antifungal therapeutic ✓ Authored an invited, highly cited review of historical development of antifungal Nikkomycin Z (NikZ).✓ Designed 30 in vitro experiments and co-authored 9 scientific papers significantly advancing the knowledge of NikZ.✓ Managed preparing and filing an FDA human Phase 1 Clinical Study Report (CSR), and six annual progress reports plus other filings, organized and organized an FDA Type C meeting (post Phase 1).• Invented and led design of novel dosing experiments to test rapid-clearance drugs by simple methods convenient for multi-week-duration, high-frequency dosing in mice ✓ Invented new, significantly more efficacious dosing protocol, enabling >80% reduction in dose and superior survival, confirmed in animal testing, reported in 5 papers and 4 patent applications✓ Designed and implemented pharmacokinetic, pharmacodynamic, modeling and simulation studies, resulting in a patent filing, and superior clinical outcomes.• Collaborated, designed drug test protocols, and strategized enrollment for dogs and humans: coordinating testing in animal models of dogs suffering with natural disease that closely represents human disease and response. ✓ Collaborated with a leading veterinarian and coordinated therapeutic protocol design and refinement, subject enrollment, predicting and tuning dose response levels to eliminate valley fever in five very sick, non-responding dogs, reported in 2024 at a major conference • Improved manufacturing strategy making and purifying NikZ in higher yields✓ Redesigned and refined purification process for nikZ drug production proven at 1- to 50-gram scale in 3,000 personal hours at the bench ✓ Collaborated to optimize large-scale manufacturing to 5 kilogram scale up towards commercial✓ Collaborated to design and test next generation formulations for human testing, with full attention to cGMP and CMC requirements for FDA filing.

• As Chief Operating Officer, led corporate operations: Applying experience from Apple and as VP at startups, organizing and managing corporate direction and strategy✓ Strategic planning and investor outreach✓ Review and implementation of multiple proposed corporate sale opportunities including two that came close to consummation.• As Chief Legal Officer, led corporate law, Patent Law, FDA Regulatory: Applying experience of taking a company public and 4 years as general counsel, IP counsel at Apple and VP at startups, organizing and managing corporate agreements, disclosures, vendor agreements and FDA regulatory✓ Organized corporate formation and reporting, organized and managed corporate Board Meetings, agenda, notices, minutes for more than 30 meetings.✓ Managed legal engagement of vendors, including reporting and progress tracking.✓ Corporate Strategy and Operations: managed outside lawyers, engaged in merger discussions four times.• As Chief Financial Officer, led financial planning, budgeting and execution: Organized accounting for development projects funded by the NIH ($8M) plus others ($1M) ✓ Established precise financial records and procedures, expertly coordinated five Circular 133A audits.✓ Organized and managed our grants administration team

Invited speaker on clinical trial design and operations, supply chain, agile processes from software to clinical trial design to operations, and more. Outsourcing Clinical Trials is presented annually in the SF Bay Area, with several companion meetings in other regions. Clinical Trial Supplies is similar, both conferences organized by Arena International. The conferences focus on clinical trial operations and outsourcing - how and why to run a clinical trial, what tools to use, choice of vendors, how to solve problems, and how to anticipate problems you did not expect you would need to.I have spoken at these conferences in San Francisco and San Diego more than 15 times. I have chaired the 2-day meetings more than 10 times. I have moderated more than 4 panels and 3 roundtable discussions.* Flexible and confident speaker, moderator, and conference organizer, with my distinctive, resonant voice commanding attention, I am frequently invited back as I keep presentations strictly on time and manage Q&A efficiently to support the speaker and educate the attendees. My presentations include the following, and more.* Clinical Trial Operations, including data collection (EDC), data management (eTMF), reporting (FDA regulatory) topics in 10 presentations* Clinical Trial Design, including Adaptive trial design and Agile trial design and operation, in 3 presentations.* Financing a small company, through investors or grants, in 3 presentations* Business Planning, particularly supply chain planning, design, tracking, feedback for improved design, IOT, and BIM dashboard integration in 7 presentations.

Since 2010 I have been a resource for the University of Arizona College of Pharmacy with a focus on entrepreneurship and drug development.

Nominated for startup of the year early in our contribution to human safety trials for our antifungal therapeutic, VFS has been nurtured by AzBIO, keeping us in close contact with the vibrant Arizona Life Sciences community. * Communicating company solutions to lay audiences at the White Hat investor conference for 5 conferences in a row* Charitable pay it forward collaboration in panel discussions of the value of vaccination, talking about the impact of my polio leaving me with a moderate limp, featured as a guest 3 times and 1 time as moderator * Representing Arizona Life Sciences at national meetings as part of the Phoenix / AzBIO team at BIO in Philadelphia 2019.

Collaborate with students and faculty, sharing my experience of years of drug development while learning new ways to make new therapeutics.• Cutting edge methods of protein design and expression, particularly de novo proteins, design and test activatable antimicrobial and cell penetrating peptides with various payloads. ✓ Practiced DNA design, protein expression in E coli, isolation and testing, cell culture, confocal microscopy, peptide synthesis and purification, testing against fungi and bacteria✓ Designed 80 peptides, expressed 40, tested 5 in detail✓ Designed radiopharmaceutical theranostic chelating 64Cu or 99m-Tc to DOTA-coupled peptides• Building on earlier 4 years PhD study departing with an MS, total 5.5 years to complete PhD. ✓ Some of the earliest work in PEGylation (polyethyleneglycol linkers and modifiers), including a PEGylated marker to evaluate kidney function, and making the first PEGylated lipids, later the basis for Doxil and the shell of the mRNA vaccines against COVID.✓ Made radioactive iodinated markers to trace new diagnostic candidate, worked with gamma and alpha emitting isotopes, leading to a publication incorporated into my thesis.

CIMR was founded in the 1960s to support medical research particularly supporting physicians and researchers at the Santa Clara Valley Medical Center in California. in continuing research for Valley Fever Solutions, to test a new dosing protocol in 2019 I engaged CIMR to test nikkomycin Z (nikZ), an antifungal drug, in a medical development project to support Phase 2 human clinical trial design.• Led design of novel dosing experiments to facilitate simple, extended-duration, high dose frequency testing of rapid-clearance drugs ✓ Designed 30 experiments, secured support to run 20 of them, and co-authored 9 scientific papers (including 4 as second author), significantly advancing the knowledge of antifungal NikZ.• Supported management through service on Board and important operational committees. Served as CIMR Trustee (2020-2021) and Board Member (2021-2023), member of the Institutional Animal Care and Use Committee (IACUC) and Biological Safety Committee (2020-2023)

California Life Sciences Association (CLSA) was formed in 2015 when BayBio merged with the California Healthcare Institute (CHI). In my role as a Fellow at California Life Sciences Association (CLSA), I was selected for the Spring 2018 Fellows All Star Team (FAST) business enhancement program, working with 12 advisors experienced in startup and life science companies to improve our business concept and execution. We met 10 times in 4 months, culminating in a conference presentation by the 6 selected companies.* Business analysis through rigorous research of competitors and our own strengths and weaknesses, opportunities and threats (SWOT) distilled into 2 slides of our presentation* Strategic planning through curated business financial projections and anticipation of challenges growing through Phase 2, and 3 trials to commercialization.* Market analysis of the competitive landscape, crafting a message to highlight values of our drug and limitations of the competing drugs distilled to a 1 page comparison chart.* Compact communications focusing on the classic 10 to 12 slide pitch deck: problem, solution, challenges, finances, and plans, presented at a FAST conference.

BayBio is very helpful to startup entrepreneurs. Networking and opportunities are great!

UCSC Extension has a rich program for pharmaceutical practices. This week long class was a useful refresher, with perspective building on my PhD training at UCSF and my experience running a small drug company for years, plus a start-up medical device effort.* Clinical Trial Design looking at how drugs are discovered, FDA INDA preparation and filing, ✓ Medical Device design and approval: 510(k) and PMA pathways, strategic planning for each.✓ GMP and GXP practices, reinforcing years of practice at VFS with large vendors, ✓ Separate program: (2008-2009) 3 10-week ASQ courses including QA, CAPA, FDA procedures and how to manage these.

In addition to contributing to growth of FORM and VRST, two NASDAQ companies, I was a founder of several startup groups, some reached investor discussions with VCs.✓ Supply chain optimization – LeanCog organized as consulting group to major conservation group designing improved supply chain tracking to manage “this fish” information from the moment caught (where, by whom) to the diner’s plate ✓Medical Device ophthalmic surgery prototype 2009: 6-month start-up experience looking to commercialize a trabechtome for eye surgery to relieve intra- ocular pressure, with detailed business market research and 3 VC presentations. EyeSys Solutions✓ System optimization mapping components and changes within complex systems including cities, airplanes, international distribution – software modeling of variable granularity. Presented to some investors including one top tier VC.

I have mentored several companies as well, more or less one a year from 2008 to about 2013.* BlueJoule solar company placed well but not first* Mentored Lean Launch Pad (founded by my Professor Steve Blank and MBA classmate Bhavik Joshi) methods to 4 CleanTech applicant groups

Manage legal contracts and other matters, mostly sales support, some real estate, a major fab expansion contractor project,

Studying voice over, better to use my "radio voice"

Solar energy company aimed to revolutionize Smart Grid integration with a cutting-edge inverter and CPV efficiency tools, assembled a talented team including the HDMI inventor, secured initial funding, but with too-early and too-late products ultimately dissolved.• Organized and incorporated company, key hiring, set up books, reporting, corporate structure, engineering.✓ Presented to 5 top-tier Venture Capital firms, securing a key Angel investment, and became a semi-finalist in the Clean Tech Open competition (placing second in category), later mentoring other teams.• Positioned to streamline solar power integration into various systems, enhancing utility and flexibility.✓ Developed an advanced inverter to convert solar panel DC output into flexible AC power and created a Smart Grid solar power sharing pool for campus and community load balancing.• Created key tools for Concentrating Photovoltaic systems to optimize tracking precision.✓ Precise tracking makes solar collection 30% more effective. Too early for market at the time.

VP, General Counsel of an international company, listed on Nasdaq, sold 4/9/05 to Cadence Design SystemsOrganized in-house legal function, managed legal aspects of acquisitions and mergers, Board issues, corporate securities, M&A, leasing, commercial matters, and stock administration, as well as legal function with offices in Israel, Paris, Munich, London, Tokyo, opened new offices in China, Toronto, Singapore, and Stockholm.• Managed all legal functions, Legal Strategy, IP Strategy.✓ Answering directly to CFO and dotted line to CEO, developed and implemented corporate legal strategy.✓ Strategy evolved from preparation for S-1 (my entry task) through 2001 IPO, business expansion both organic and by acquisition, international expansion, and 2005 >$300M sale to Cadence Design Systems.✓ Managed legal issues in many countries for our Israeli company with Silicon Valley co-headquarters, expanding in Europe and Asia – Pacific.✓ Assisted in preparing and managing board materials, took and produced minutes for Board and committee meetings.• Directed corporate governance and compliance.✓ M&A Transactions, worked through screening potential targets, managed two at $80M and $300M.✓ Developed and honed expertise in corporate law, collaborating with outside counsel and printers, coordinating all SEC filings - 4 yrs✓ Directed and managed legal side of SEC filings, Section 16, 10 K’s and Q’s, SOX compliance.• Developed and led experienced corporate law team.✓ Wrote and managed key sales contracts, plus corporate agreements, real estate, licensing agreements, and vendor contracts.✓ Developed and led a very effective internal legal team and managed close-knit, excellent representation by top outside attorneys for corporate, securities, tax, IP, and HR, as well as general law issues.✓ Hired excellent paralegals and attorneys in house to manage legal matters✓ Established a contract database, particularly for MSAs and CDAs, and provided fast responses to sales teams.

FormFactor was just getting established and later dominated the probe card market. IPO 2003, Market value 2024 $3.8BOrganized in-house legal function, focus on patent strategy and broad protection, handled every day legal matters, attended Board meetings, led key contract negotiations with major customers.• Legal strategy, focusing on developing and growing a patent portfolio.✓ Answering directly to the CEO, developed and implemented corporate legal strategy.✓ Divided an early omnibus patent application into about 10 initially and over time about 25 applications, plus protecting many new developments for a portfolio of about 100 properties.✓ Portfolio later blocked a key competitor, valuing some $100M to FormFactor.✓ Worked closely with the Commissioner of Patents and Trademarks, a friend and colleague from work we had done together some years earlier.• Managed Legal Affairs and key contracts.✓ Deeply involved in major contracts with partners and vendors, key to growing sales from $10M to $100M.✓ Supported and assisted in the development and integration of our first ERP system.

Apple was struggling a bit with interim leaders in my time there but still had amazing innovation and employees. I left just before Steve Jobs came back and started his incredible transformation of Apple.Managed patent issues for the largest division of Apple Computer, > 60% of corporate revenue, and a personal computer division staff member (40% of corporate revenue).• Managed and grew a large portfolio of patents for division and product technologies.✓ Tasked with finding innovation, successfully encouraged managers and ICs to support broad patent filing efforts. ultimately coordinating the preparation and filing of over 50 patents my first year.• Represented legal department on key VP staff, division generating 40% of corporate revenue.✓ Participated closely in management review and operation of ~5,000-person division.✓ Participated closely in the selection of candidate technologies and the choice of commitment to develop prototypes for sales and then continuing commercial operations, including life cycle management through end of life.• Lead candidate for promotion to Chief IP Counsel.✓ Acting head of IP when the Chief IP Counsel was away, either of 2 of us in our group of 11 could have stayed and moved into that position.

IP Law, Chair East Bay Network for Entrepreneurs, 4 years helping build the IP department* Brought in and managed more billings than my compensation* Led "East Bay Technology Entrepreneurs Network" training and presenting startups at our annual investor conference

IP work for top tier Silicon Valley companies, Brown & Bain at the time, under Roger BorovoyWrote and filed the first Rambus patent application, 1990, specification for >50 issued patentsFiled and prosecuted most of Adobe's first ~ 20 patent applications

Fish & Neave at the time, now a group within Ropes and Gray. Mostly Fortune 10 work.* International patent prosecution* Biotech (Genetic modifications), Pharmaceuticals (small molecules), Technology, Heavy industry (Fortune 10 clients including Exxon, AT&T, Fish represented 7 of the 10)* Mostly litigation, some prosecution, some business strategy